author-photo

H. Zhang

Pfizer

18

Papers

533

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

OA 05.01 First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
P3.01-072 Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR+ NSCLC in Japanese Patients (ARCHER 1050)

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (43)
97OEGFR MUTANT SUBSET ANALYSIS FROM ARCHER 1009: A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF DACOMITINIB VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

2015 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

2015 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (173)
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial

2014 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (14)
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

2014 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (85)
Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (14)
IS7. lung cancer

2012 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Dacomitinib (PF-00299804), An Irreversible Pan-Her Tyrosine Kinase Inhibitor (TKI), For First-Line Treatment of EGFR-Mutant or Her2-Mutant or -Amplified Lung Cancers

2012 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (20)